GlycoMimetics Inc News - GLYC | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
GlycoMimetics Inc (GLYC)
GlycoMimetics Inc (GLYC) News

GlycoMimetics Inc (GLYC)

0.3765

-0.0135

(-3.46%)

Closed 07 November 8:00AM

Delayed by 15 minutes

0.418

0.0415

(11.02%)

After Hours: 11:59AM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement

A Maryland-based biotech company is already dominating Tuesday’s session prior to the opening bell after it was announced that the company...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with...

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

1
Next

TechandBio

TechandBio 1 week ago

GLYC Sold at .60 yesterday for 203% profit.

Next micro cap buyout or hostile take over will be BFRI interesting price action after hours FDA approved drug for AK skin cancer with late stage pipeline for Basil Cell and Squamous cell carcinoma Phase 3 and Acne Phase 2 call your dermatologist I bet they use Ameluz
the FDA also just green lighted 3 tubes can be used in a single session from 1 $400 a tube =$1200

https://www.biofrontera-us.com/research/product-pipeline

https://www.investing.com/news/company-news/biofrontera-locks-phase-3-sbcc-study-database-for-analysis-93CH-3662035

https://us.ameluz.com/
$GLYC

INV4

INV4 1 week ago

Bought some more GLYC this morning.

================

Biotech Up Over +100% Premarket Following Merger And Funding Announcement

Tuesday, October 29, 2024

A Maryland-based biotech company is already dominating Tuesday’s session prior to the opening bell after it was announced that the company will be merging with Crescent Biopharma and that it secured approximately $200 million in funding to financing operations through 2027, according to this morning’s release.

Traders were quick to snatch up shares of GlycoMimetics Inc. (Nasdaq:GLYC), with the current bid sitting at $0.3694/share (+119.62% implied open for sellers) at the time of writing. It should be an exciting session for this micro cap!

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

https://www.allpennystocks.com/specialreportsus/3692/biotech-up-over-100-premarket-following-merger-and-funding-announcement?utm_source=advfn

$GLYC

dennisv

dennisv 1 week ago

Renewed Opportunities!

hondaboost

hondaboost 1 week ago

My tons of GLYC shares at $0.17 now have Huge gains!!! Go, go, go!!!!!

dennisv

dennisv 1 week ago

dennisv

dennisv 1 week ago

There is a lot of room.
Let's do it!

tw0122

tw0122 1 week ago

Up 200% 09:44 AM EDT, 10/29/2024 (MT Newswires) -- GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.

glenn1919

glenn1919 1 week ago

glyc....................................https://stockcharts.com/h-sc/ui?s=glyc&p=W&b=5&g=0&id=p86431144783

Sierra20

Sierra20 4 months ago

Bankruptcy proceedings next. You been warned. Check out my latest post.

hondaboost

hondaboost 4 months ago

GLYC was $3.5 in Jan. Institutions and mutual funds holding 50 million shares at dollars, out of 64 million OS.

hondaboost

hondaboost 4 months ago

GLYC, Chief Medical Officer bought 310,000 shares at $0.26 at open market on June 21. He must know something.

https://www.otcmarkets.com/filing/html?id=17638385&guid=RXO-kWK48IECJth

Invest-in-America

Invest-in-America 4 months ago

GLYC: Article here ---
https://www.defenseworld.net/2024/06/25/glycomimetics-inc-nasdaqglyc-insider-edwin-rock-buys-190000-shares.html#google_vignette

TheFinalCD

TheFinalCD 4 months ago

you usually post the bottom charts before they go

tw0122

tw0122 4 months ago

Hitting .43s looking good

Sierra20

Sierra20 4 months ago

Delisting letter coming. You have been warned.

glenn1919

glenn1919 4 months ago

GLYC............................https://stockcharts.com/h-sc/ui?s=GLYC&p=W&b=5&g=0&id=p86431144783

subslover

subslover 4 months ago

Nice insider buys here = https://www.otcmarkets.com/filing/html?id=17638385&guid=NwO-kFXCNX90B3h

Monksdream

Monksdream 6 months ago

spindog

spindog 6 months ago

Well? Good thing i held off on taking a position….

Monksdream

Monksdream 7 months ago

Gotta wait it out

spindog

spindog 7 months ago

Hopefully the FDA will give GLYC the the green light after reviewing phase 3 data in June

Monksdream

Monksdream 7 months ago

Monksdream

Monksdream 7 months ago

willlbone

willlbone 2 years ago

INFINITI

INFINITI 2 years ago

TechandBio

TechandBio 2 years ago

Picked up a few heavy racks of shares under 2.95 today.

$GLYC

Invest-in-America

Invest-in-America 2 years ago

GLYC: Hey!!!! WHAT???? (HA-HA!!)

makinezmoney

makinezmoney 2 years ago

$GLYC: The chart is screaming bullflag breakout on 100day chart

Now at 2.50

Perfect BULL FLAG.

NICE

GO $GLYC

TommyBoyTrader9460

TommyBoyTrader9460 2 years ago

$GLYC Crazy runner here..on watch to see if it continues as insider bought a ton of shares..

https://stocktwits.com/soll/message/497100283

https://stockcharts.com/c-sc/sc?s=GLYC&p=D&b=5&g=0&i=0&r=1668953354914

Invest-in-America

Invest-in-America 2 years ago

gail

gail 2 years ago

yup and congrats on your other runner.

Invest-in-America

Invest-in-America 2 years ago

GO-GO-GO-GLYC!!!

PS: Hey, Girl, tap my latest POSTS behind @GRND --- what a SPECTACLE that one is!!!! (I grabbed their WARRANTS!!)

gail

gail 2 years ago

looking good here.

gail

gail 2 years ago

wow, new highs hitting right now!

gail

gail 2 years ago

and back to 2 bucks. lets see what tomorrow brings.

gail

gail 2 years ago

boing, and back up she goes.

gail

gail 2 years ago

manipulation bringing it …

..

down but lets see what happens.

gail

gail 2 years ago

here we go, breaking 2 bucks big time now.

gail

gail 2 years ago

its time to break 2 bucks and really move like it did in the past.

1hot toddy

1hot toddy 2 years ago

WOW WOW WOW CHIEF MEDICAL OFFICIER BOUGHT 200,000 SHARES $$$

he went from 0 shares to 200000 in two days. 2- 100000 shares buys 2 days

now 4 employees have bought shares.

1hot toddy

1hot toddy 2 years ago

WOOOOOOOOOOOOOOOOOW 63000 SHARE BUY $$$$$$$$$$$$$$$$

employees are buying toooooooooo

1hot toddy

1hot toddy 2 years ago

3 HUGE INSIDE BUYS BY 3 PEOPLE. 19K, 20K AND 25K $$$$$$$$$$$$$$$$

1.06/1.29 UP UP AND AWAY

willlbone

willlbone 3 years ago

Back to 99 cents.

MfridgeV2

MfridgeV2 4 years ago

Agreed. Things looking up. Load up while no one else wants it. ;)

fishhunter

fishhunter 4 years ago

Now is but time. The gap has filled, weak hands are out, corporate path is correct.

mining101

mining101 4 years ago

Depends at what level - if back to 2s first it’s a big loss till then

stockguard

stockguard 4 years ago

The Investment Case For GlycoMimetics
https://seekingalpha.com/article/4389595-investment-case-for-glycomimetics

whytestocks

whytestocks 4 years ago

News; $GLYC GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

Data highlight the importance of early intervention with E-selectin inhibitors to disrupt inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) Additional presentations highlight multiple E-selectin inhibition strategies and their pot...

In case you are interested GLYC - GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

fishhunter

fishhunter 4 years ago

Great buy at this price. I own a ton of it.

whytestocks

whytestocks 4 years ago

News; $GLYC New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

- Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and...

In case you are interested GLYC - New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions